

June 5, 2020

Listing Department

**Code: 532 321**

**BSE LIMITED**

P J Towers, Dalal Street, Fort,  
Mumbai – 400 001

Listing Department

**Code: CADILAHC**

**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai – 400 051

**Re.: Press Release**

Dear Sir/Madam,

Please find enclosed a copy of press release dated June 5, 2020 titled “Zydus Cadila receives final approval from USFDA for Atazanavir Capsulres”.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**



**DHAVAL N. SONI**  
**COMPANY SECRETARY**



**Encl.: As above**

## Zydus Cadila receives final approval from USFDA for Atazanavir Capsules

Ahmedabad, June 5, 2020

Zydus Cadila has received final approval from the USFDA to market Atazanavir Capsules (US RLD: Reyataz™ Capsules) in the strengths of 150 mg, 200 mg and 300 mg.

Atazanavir, an antiretroviral drug, is used to treat infection of the Human Immunodeficiency Virus (HIV). It is used in combination with other antiretroviral drugs to treat HIV-1 infection.

The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has 291 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

### About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*